<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170314033069N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-31</date_registration>
      <primary_sponsor>Vice President of Research Guilan university of medical sciences</primary_sponsor>
      <public_title>The effect of ketamine on bleeding and oxytocin consumption during cesarean section</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the prophylactic effect of intravenous ketamine on the amount of bleeding and intravenous oxytocin consumption in elective cesarean section</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>210</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52609</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method of initial selection of individuals to enter the project will be in the form of convenience sampling of pregnant women who are candidates for elective cesarean section by regional anesthesia method. Eligible patients will be divided into two groups of ketamine and normal saline (control) using block size of 4, created by the computer and WinPepi Ver.11.65 software which is prepared by the methodology consultant, Blinding description: In this study, the patient and the evaluator are unaware of the treatment groups. The evaluation will be performed by an anesthesia assistant. drugs include ketamine and normal saline will be prepared by a trained anesthesia technician who is not in the study, in exactly the same syringes, and from a list of eligible patients, one by one from each group using a random list. After that it will be given to the anesthesia assistant.ِDrugs will be injected to the patients of both groups, Immediately after the umbilical cord clamp.
The number of oxytocin units, primary outcomes (bleeding rate based on changes in hemoglobin levels) before and after surgery as well as secondary outcomes (complications such as nausea, vomiting, hallucinations) during surgery and in recovery will be recorded by the anesthesia assistant.</study_design>
      <phase>3</phase>
      <hc_freetext>Maternal care to reduce bleeding during cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Eligible patients first receive adequate explanations of this research and then informed consent is obtained. After the baby's birth, oxytocin will be given at a rate of 0.4 units per minute. Then immediately after the umbilical cord clamp, 0.25 milligrams per kilogram of intravenous ketamine (Ampule 500 milligram in 10 milliliters, manufacturer: Sterop, country: Belgium) will be prescribed. Intervention 2: Control group: Eligible patients first receive adequate explanations of this research and then informed consent is obtained. After the baby's birth, oxytocin will be given at a rate of 0.4 units per minute. Then immediately after the umbilical cord clamp, 2 milliliters of intravenous normal saline will be prescribed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Gelareh Biazar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3332 9524</telephone>
        <email>gelarehbiazar1386@gmail.com</email>
        <affiliation>Anesthesiology Research Center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Gelareh Biazar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3332 9524</telephone>
        <email>gelarehbiazar1386@gmail.com</email>
        <affiliation>Anesthesiology Research Center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women candidates for elective cesarean section
Regional anesthesia method</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Reluctant to participate in the project
allergic to ketamine
history of seizures
history of psychological illnesses</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O26</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Maternal care for other conditions predominantly related to pregnancy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Eligible patients first receive adequate explanations of this research and then informed consent is obtained. After the baby's birth, oxytocin will be given at a rate of 0.4 units per minute. Then immediately after the umbilical cord clamp, 0.25 milligrams per kilogram of intravenous ketamine (Ampule 500 milligram in 10 milliliters, manufacturer: Sterop, country: Belgium) will be prescribed.</i_keyword>
      <i_keyword>Control group: Eligible patients first receive adequate explanations of this research and then informed consent is obtained. After the baby's birth, oxytocin will be given at a rate of 0.4 units per minute. Then immediately after the umbilical cord clamp, 2 milliliters of intravenous normal saline will be prescribed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding rate. Timepoint: Before and after surgery. Method of measurement: Based on changes in hemoglobin levels.</prim_outcome>
      <prim_outcome>Oxytocin consumption. Timepoint: At the end of surgery. Method of measurement: Units per minute.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Complications(nausea, vomiting and hallucination). Timepoint: During operation and in recovery. Method of measurement: observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice President of Research Guilan university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-25</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street,Rasht Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
